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Breast cancer is the most common invasive cancer in women worldwide. It is the second leading cause 
of cancer death in women. Most frequently it metastasizes to the liver, lungs, bones, brain and lymph 
nodes. The treatment depends on the tumor’s subtype, including hormone receptor status, such as 
estrogen and progesterone and HER2 status. Furthermore, it depends on the stage of the tumor, genomic 
markers, patient’s age, general health, and menopausal status. The patient is a 31-year old female who 
was diagnosed with invasive breast cancer and underwent surgery at the end of 2015. PHD showed an 
invasive cancer with estrogen and progesterone receptor positivity of 70%, Her2+ luminal B and 
T2N1M0. She was treated with adjuvant chemotherapy with doxorubicin and cyclophosphamide, along 
with pegfilgrastim, paclitaxel and transtuzumab. Afterwards, she had radiotherapy, 50Gy in 25 
fractions. Next, she got adjuvant hormone therapy with tamoxifen and goserelin, later replaced by 
exemestane. In 2017, she had endometrial hyperplasia and underwent curettage. Because of 
metrorrhagia she had hysteroscopy with polypectomy and myomectomy. At the beginning of 2019, she 
had severe headaches so MSCT was done. She was diagnosed with metastatic brain tumor in the right 
parietal lobe, Her2+ and ER and PR negative. The patient is now recovering from brain surgery and 
stereotactic radiosurgery is being considered. Solitary brain metastasis without visceral metastases 
requires a specialized management approach. Systemic therapy is continued, and local treatment is 
added, resection followed by radiotherapy. 
 
 
 
 
 
  
